Cuu Long Pharmaceutical JSC (DCL)

Currency in VND
23,050.0
0.0(0.00%)
Real-time Data·

DCL Financial Summary

Key Ratios

P/E Ratio29.78
Price/Book1.11
Debt / Equity50.5%
Return on Equity3.79%
Dividend Yield0.00%
EBITDA97.69B
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2015
31/12
2016
31/12
2017
31/12
2018
31/12
2020
01/01
2021
01/01
2021
31/12
2022
31/12
2023
31/12
2024
31/12
* In Millions of VND (except for per share items)

Earnings

Latest Release
Apr 29, 2025
EPS / Forecast
342.45 / --
Revenue / Forecast
340.02B / --
EPS Revisions
Last 90 days

FAQ

What were Cuu Long Pharmaceutical's earnings for the latest quarter?

The Cuu Long Pharmaceutical EPS (TTM) is 772.76. Cuu Long Pharmaceutical reported sales of 340,016.73, net income of 25,012.71, and EPS of 342.45 for the latest quarter.

What was Cuu Long Pharmaceutical's net income for the latest quarter?

Cuu Long Pharmaceutical's net income for the latest quarter was 25,012.71.

How did Cuu Long Pharmaceutical's performance compare year-over-year in the latest quarter?

The company's revenue moved from 510,263.16 in the previous quarter to 340,016.73 in the latest quarter, and net income moved from 18,924.62 to 25,012.71 compared to the previous quarter.

What is Cuu Long Pharmaceutical's net profit margin on a TTM basis?

Cuu Long Pharmaceutical's trailing twelve months (TTM) net profit margin is 4.10%.

How does Cuu Long Pharmaceutical's debt to equity ratio compare to industry standards?

Cuu Long Pharmaceutical's total debt-to-equity ratio is 50.50%.

What is Cuu Long Pharmaceutical's return on investment on a TTM basis?

Cuu Long Pharmaceutical's trailing twelve months (TTM) return on investment (ROI) is 3.79%.

Did Cuu Long Pharmaceutical gain or lose cash last quarter?

In the latest quarter, Cuu Long Pharmaceutical's net change in cash was -36,383.05 million.

What were Cuu Long Pharmaceutical's total assets and liabilities in the latest quarter?

As of the latest quarter, Cuu Long Pharmaceutical reported total assets of 2,463,064.68 million and total liabilities of 691,967.61 million.

How has Cuu Long Pharmaceutical's total revenue grown this year?

Cuu Long Pharmaceutical's total revenue was 510,263.16 in the previous quarter and 340,016.73 in the latest quarter.

What is Cuu Long Pharmaceutical's gross margin on a TTM basis?

Cuu Long Pharmaceutical's trailing twelve months (TTM) gross margin is 16.18%.

What was Cuu Long Pharmaceutical's revenue per share for the latest quarter?

Cuu Long Pharmaceutical's revenue per share for the latest quarter was 29,370.22.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.